Lipid Luminations

Host: Alan S. Brown, MD, FNLA Live from the Clinical Lipid Update of the National Lipid Association in Amelia Island, FL, host Dr. Alan Brown welcomes Dr. Robert Kloner, Vice President of Translation at Huntington Medical Research Institutes and Professor of Medicine in the Cardiovascular Division of Keck School of Medicine at the University of Southern California. Dr. Kloner discusses the cardiovascular risk factors associated with erectile dysfunction, safety and efficacy of erectile disfunction drugs, and benefits vs risks of supplementing with testosterone.

Host: Alan S. Brown, MD, FNLA Live from the Clinical Lipid Update of the National Lipid Association in Amelia Island, FL, host Dr. Alan Brown welcomes Dr. Rhoda Cooper-DeHoff. Dr. Cooper-DeHoff is an Associate Professor in the Department of Pharmacotherapy and Translational Research and Division of Cardiovascular Medicine of the Colleges of Pharmacy and Medicine at the University of Florida. She is also Associate Director of the Center for Pharmacogenomics at this institution. Dr. Cooper-DeHoff discusses the rise of pharmacometabolomics, genomic testing, and pharmacogenetic testing in lipidology, with particular emphasis on predictive mapping for statin responses.

Host: Alan S. Brown, MD, FNLA Live from the Clinical Lipid Update of the National Lipid Association in Amelia Island, FL, host Dr. Alan Brown welcomes Dave Dixon, PharmD, Clinical Pharmacist and Associate Professor of Pharmacology at Virginia Commonwealth University School of Pharmacy. Dr. Dixon is also a Board Certified Pharmacotherapy Specialist, Clinical Lipid Specialist, and Fellow of the National Lipid Association. He serves as a Regional Representative for the Southeast Chapter of NLA and on the Journal of Clinical Lipidology Editorial Board. Dr. Dixon discusses guidelines for treating hypertriglyceridemia, effective therapies for reducing triglyceride levels, and emerging lipid-lowering therapies in development.

Host: Alan S. Brown, MD, FNLA Live from the Clinical Lipid Update of the National Lipid Association in Amelia Island, FL, host Dr. Alan Brown welcomes Dr. Eugenia Gianos. Dr. Gianos is an assistant professor in the Department of Medicine and co-clinical director of the Center for the Prevention of Cardiovascular Disease at the NYU School of Medicine. Dr. Gianos discusses the effectiveness, potential side effects, and patient outcomes with PCSK9 antibodies for management of dyslipidemia.

Host: Alan S. Brown, MD, FNLA Like in the United States, Canadian citizens contend with a high pediatric prevelance of lipid disorders, particularly familial hypercholesterolemia. However, perspectives on clinical care and standards public health priorities to address dyslipidemia differ markedly between these two countries. Can American practitioners and health policy experts alike benefit from Canadian approaches to lipidology? Dr. Alan Brown welcomes Dr. Julie St. Pierre, Professor of Pediatrics at Sherbrooke University in Canada, to discuss pediatric lipid disorder management across North American borders.

Host: Alan S. Brown, MD, FNLA Patients in lipidolgy clinics sometimes undergo diagnostic workups for mild liver enzyme elevations, and in select cases a diagnosis of non-alcoholic fatty liver disease will be made. How does this diagnosis compare with the more inflammatory alcoholic fatty liver disease, and what roles should the lipidologist play in response to these findings? Dr. David Cohen, Professor of Medicine at Harvard Medical School and Director of Hepatology at Brigham and Women's Hospital, joins host Dr. Alan Brown to discuss the pathogenesis and management of non-alcoholic fatty liver disease.

Host: Alan S. Brown, MD, FNLA Joining Dr. Alan Brown to discuss the pharmacokinetic data behind drug interactions between treatments for complex lipid abnormalities is Dr. Barbara Wiggins, Pharm.D, clinical pharmacy specialist in cardiology at the Medical University of South Carolina and adjunct professor at the South Carolina School of Pharmacy. Dr. Wiggens has served as a member of the cardiovascular expert panel for the United States Pharmacopoeia.

Host: Alan S. Brown, MD, FNLA Guest: Robert Wild, MD, MPH, D.Phil. Recorded live at the recent Annual National Lipid Association meeting, Dr. Alan Brown welcomes Dr. Robert Wild to discuss types of dyslipidemia that clinicans may see in women of child bearing age, particularly those using hormonal contraception. The two discuss ways for clinicians to trace the source of dyslipidemia in these women, from primary to secondary causes, and how this knowledge can guide future contraception choices. Dr. Robert Wild is Professor of OB/GYN and Adjunct Professor in Biostatistics and Epidemiology at the University of Oklahoma. He is also Adjunct Professor in Epidemiology at the University of Pittsburgh, and Adjunct Professor of Nutrition at Oklahoma State University.

Host: Alan S. Brown, MD, FNLA Guest: Joyce Ross Host Dr. Alan Brown welcomes Joyce Ross, nurse practitioner and President of the National Lipid Association. Joyce is a consultative education specialist in Cardiovascular Risk Intervention with the University of Pennsylvania Health System. She is the first Nurse Practitioner elected as President of the NLA. Ms. Ross introduces her goals for the upcoming year, including novel efforts on behalf of the NLA to help combat America's obesity epidemic.

Host: Alan S. Brown, MD, FNLA Host Dr. Alan Brown welcomes Dr. Seth Martin, cardiologist and assistant professor of medicine at the Johns Hopkins University School of Medicine with a joint appointment in epidemiology at the Johns Hopkins Bloomberg School of Public Health. Dr. Martin is a faculty member in the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease. Dr. Martin discusses the pursuit of lipid profiles on a national level, utilizing Big Data from health records and clinical trials to develop better understandings of cardiovascular risk and theraputic efficacies.

Host: Alan S. Brown, MD, FNLA Guest: Joyce Ross, MSN, CRNP, CS, CLS, FNLA, FPCNA Host Dr. Alan Brown welcomes Joyce Ross, MSN, CRNP, FNLA, President-Elect of the National Lipid Association. Joyce serves as a consultative education specialist in cardiovascular risk intervention with the University of Pennsylvania Health System. Their discussion focuses on lipid management to reduce atherosclerotic cardiovascular disease (ASCVD) risk in elderly patient populations. Thhis interview was recorded live at the National Lipid Association in San Diego, California for the 2016 Spring Clinical Lipid Update.

Host: Alan S. Brown, MD, FNLA Dr. Alan Brown welcomes Dr. Penny Kris-Etherton, Distinguished Professor of Nutrition at Penn State and Past President of NLA. Dr. Kris-Etherton reviews the current dietary recommendations for saturated fat for the population at large and for reducing LDL-C levels. The two discuss the evidence to support these dietary recommendations and optimal replacement nutrients for dietary saturated fatty acids (SFAs).

Host: Alan S. Brown, MD, FNLA Host Dr. Alan Brown welcomes Dr. Steven Nissen, Chairman of the Department of Cardiovascular Medicine and Professor of Medicine at the Lerner School of Medicine of the Cleveland Clinic. The two focus on some of the major developments in lipidology today, from roles of intravascular ultrasound to updates in clinical drug trials to perspectives on past and present guideline recommendations.

Host: Alan S. Brown, MD, FNLA Guest: Harold Bays, MD, FNLA Dr. Alan Brown welcomes Dr. Harold Bays, President of the Southeast Lipid Association and President of the Louisville Metabolic and Atherosclerotic Research Center in Louisville, KY. Dr. Bays led a novel educational effort to provide an annual summary of clinical lipidology to readers of the Journal of Clinical Lipidology. With insightful commentaries of value to lipidologists and generalists alike, the annual summary is expected to pave new ground in the ongoing effort to keep clinicians up to date with the field.

Host: Patrice L Basanta-Henry, MD, MHSc, FACOG Host Dr. Patrice Basanta Henry welcomes Dr Nzinga Harrison, Addiction Medicine & Psychiatrist, Campaign Psychiatrist for Let's Get Mentally Fit!, and, the CMO of ANKA Behavioral Health Incorporated. Dr. Harrison will discuss the importance of non-pyschiatric clinicians in recoginizing mentail illness, those specific illnesses where there is a higher chance of comorbidity of psychiatric illness, and best practices & tools avaialble for health care providers.

Host: Harold Bays, MD, FNLA Dr. Harold Bays welcomes Dr, Alan Remaley, clinical pathologist and Section Chief of the Lipoprotein Metabolism Section in the Cardiopulmonary Branch of the National Heart Lung, and Blood Institute in Bethesda, MD. Their discussion centers on LDL cholesterol from a variety of little-known aspects: its history as a biomarker for disease status, the ways in which it gets specifically measured, and the rise of lipid-altering pharmacotherapies to combat excessive LDL levels.

Host: Alan S. Brown, MD, FNLA Guest: Allan Sniderman, MD Risk is calculated by a variety of algorithms, all of which produce an estimate for that individual based on age, gender, cholesterol, blood pressure, and smoking history. The estimate is critical to clinical decision-making, but how accurate is it? Host Dr. Alan Brown welcomes Dr. Allan Sniderman, Edwards Professor of Cardiology at McGill University, to discuss why we should pay more attention to the causes, and less to the risks, of cardiovascular disease. Supported by an Educational Grant from AstraZeneca.

Host: Alan S. Brown, MD, FNLA Medication Adherence: is it the Achilles Heel in your therapies for patients with dyslipidemia? Dr. Lynne Braun, nurse practitioner in the Preventive Cardiology Center and the Heart Center for Women, and Professor in the Department of Adult Health Nursing at the Rush College of Nursing in Chicago, targets three critical barriers to lipid medication adherance: weak patient-provider relationships, health illiteracy, and poor health care transitions after hospital discharge. Supported by an Educational Grant from AstraZeneca.

Host: Alan S. Brown, MD, FNLA Dr. Alan Brown welcomes Dr. Peter Jones, Associate Professor of Medicine and Atherosclorosis/Lipidology at Baylor College of Medicine in Houston, TX. They review special populations in the treatment of dyslipidemia, including Asians, women, elderly patients, and the immune-compromised. Supported by an Educational Grant from AstraZeneca.

Host: Alan S. Brown, MD, FNLA Guest: Keith Ferdinand, MD Host Dr. Alan Brown is joined by Dr. Keith C. Ferdinand, Professor at Tulane University School of Medicine in New Orleans, Louisiana. Dr. Ferdinand reviews the etiologies, diagnostic challenges, and management considerations for selective cardiac health issues prevalent in African American populations, from hypertension to coronary arterial calcium plaques to lipid levels. Supported by an Educational Grant from AstraZeneca.

Host: Alan S. Brown, MD, FNLA Guest: Joyce Ross, MSN, CRNP, CS, CLS, FNLA, FPCNA One of the most recurrent questions that cardiologists and lipidologists face in daily practice is how to best approach the elderly patient with dyslipidemia. Joining Dr. Alan Brown for special considerations in this population and guideline-based recommendations for management is Joyce Ross, certified registered nurse practitioner, clinical lipid specialist, and President-Elect of the National Lipid Association. Supported by an Educational Grant from AstraZeneca.

Host: Alan S. Brown, MD, FNLA Host Dr. Alan Brown welcomes Dr. Don Wilson, Endocrinologist at Cook Children's Health Care System, Fort Worth, Texas. Dr. Wilson will review dyslipidemia in children and adolescent patients. Key points of their discussion will cover the association between abnormal lipid levels in children and an increased lifetime risk of atherosclerotic CVD, as well as, the CVD risk factors present in children and how it tracks from childhood to adulthood. Supported by an Educational Grant from AstraZeneca. Supported by an Educational Grant from AstraZeneca. - See more at: https://reachmd.com/programs/lipid-luminations/million-hearts-initiative-dr-janet-wright-executive-director/7439/#sthash.aVHL9OOn.dpuf Supported by an Educational Grant from AstraZeneca. - See more at: https://reachmd.com/programs/lipid-luminations/million-hearts-initiative-dr-janet-wright-executive-director/7439/#sthash.aVHL9OOn.dpuf

Host: Alan S. Brown, MD, FNLA In this session of Lipid Luminations, host Dr. Alan Brown welcomes Dr. Merle Myerson, founder and director of the Cardiovascular Disease Prevention Program, Lipid Clinic, Pre-Exercise Heart Screening Program, and Cardiology Section/Institute for Advanced Medicine (HIV) at Mount Sinai St. Luke's and Mount Sinai Roosevelt Hospitals. Dr. Myerson reviews the guidelines for prevention, diagnosis, and management of dyslipidemia in patients with HIV.

Host: Alan S. Brown, MD, FNLA Guest: Janet Wright, MD Heart disease and stroke are two of the leading causes of death in the United States. The Department of Health and Human Services, with several key partners, launched the Million Hearts national public-private initiative. Million Hearts aims to prevent one million heart attacks and strokes over five years through behavioral changes and clinical interventions. Host Dr. Alan Brown welcomes Dr. Janet Wright, Executive Director of Million Hearts in Washington, DC. Supported by an Educational Grant from AstraZeneca.

Host: Alan S. Brown, MD, FNLA An old clinical dogma in OB/GYN was that dyslipidemia during pregnancy wouldn't have any long term implications on the developing fetus because of short exposures at 9 months. This has since been shown to be untrue. What health issues surface in children whose mothers experienced abnormally elevated lipid levels in pregnancy, and how can these problems be prevented at the peripartum stage? Host Dr. Alan Brown joins Dr. Robert Wild, Professor of Obstetrics and Gynecology at the University of Oklahoma College of Medicine, to discuss prevention and treatment strategies for dyslipidemia during pregnancy. Dr. Wild is past president of the American Society of Preventive Cardiology, the Society of Reproductive Endocrinologists, the Oklahoma City Obstetrical and Gynecological Society, and the Menopause Group for the American Society of Reproductive Medicine.

Host: Alan S. Brown, MD, FNLA As many as 25% of patients taking statins may experience side effects. How should clinicians respond to the broad spectrum of side effects and variable severities reported? Host Dr. Alan Brown welcomes Dr. John Guyton, Associate Professor of Medicine and Assistant Professor of Pathology at Duke University School of Medicine, to discuss statin intolerance and the most effective methods for counseling patients who experience this issue. Dr. Guyton's team has developed approaches that help many patients who have trouble taking statin drugs find alternative ways to lower their low-density lipoprotein (LDL) levels. Dr. Guyton is recognized nationally as an expert in clinical management of lipid disorders and is known for his earlier work on lipid deposition in the arterial wall.

Host: Alan S. Brown, MD, FNLA A paradigm shift in the management of lipid disorders has been witnessed of late based on evidence reviews by the AHA and the ACC. Where the clinical dogma once focused on targeting specific lipoproteins, clinicians are now trending toward using appropriate dosages of statins for lowering non-HDL cholesterol. What are the ramifications of this change in approach, and how does the NLA weigh in on recommendations for targets and goals? To address these and other questions, host Dr. Alan Brown welcomes Kevin Maki, PhD, FNLA, CLS, Chief Science Officer for Midwest Center for Metabolic and Cardiovascular Research and Adjunct Faculty in Biostatistics and Applied Epidemiology at DePaul University, Chicago, IL.

Host: Alan S. Brown, MD, FNLA What's the evidence for LDL and other non-HDL targets for primary and secondary prevention of heart disease? What are the comparative benefits versus toxicities of all lipid-lowering medications in clinical use? Addressing these and other questions from the standpoing of recent NLA recommendations is Kevin Maki, PhD, FNLA, CLS, Chief Science Officer for Midwest Center for Metabolic and Cardiovascular Research and Adjunct Faculty in Biostatistics and Applied Epidemiology at DePaul University, Chicago, IL. Produced in partnership with

Host: Alan S. Brown, MD, FNLA Guest: Carl Orringer, MD, FACC, FNLA What are some of the causes of high triglycerides? What is the biggest health risk? And, for these patients, at what level is the risk greater for developing pancreatitis and coronary artery disease? Host Dr. Alan Brown welcomes Dr. Carl Orringer, Associate Professor of Medicine at the Cardiology Division, University of Miami Medical Center and Director of the Preventive Cardiovascular Medicine and LDL apheresis program. In this edition of Lipid Luminations, Dr. Orringer will discuss the management of the patients with triglycerides 200-499 mg/dl.

Guest: Kevin C. Maki, PhD, FNLA, CLS Host: Alan S. Brown, MD, FNLA At the most recent National Lipid Association (NLA) meeting, host Dr. Alan Brown welcomes Kevin Maki, PhD, FNLA, CLS, Chief Science Officer for Midwest Center for Metabolic and Cardiovascular Research and Adjunct Faculty position in Biostatistics and Applied Epidemiology at DePaul University, Chicago, IL. Drs. Brown and Maki discuss the evidence of the relationship of statin use and risk of new onset of diabetes; as well as, the relationship of statin use and the possiblity of worsening glycemia in those patients who have diabetes. What are the conclusions? What should clinicians be screening for? Download and listen to this great conversation! Sponsored by

Guest: Anne Goldberg, MD Host: Alan S. Brown, MD, FNLA Host Dr. Alan Brown is joined by Anne Goldberg, MD, Associate Professor of Medicine at Washington University School of Medicine and a member of the ACC/AHA Blood Cholesterol Guidelines Panel. Dr. Goldberg will provide a review of the panel assembled by National Heart, Lung, and Blood Institute to construct integrated guidelines for cardiovascular risk reduction. She will also address the controversy regarding the ACC/AHA recently published risk assessment and cholesterol guidelines. Download and listen today! Sponsored by

Guest: Kevin C. Maki, PhD, FNLA, CLS Guest: Carl Orringer, MD, FACC, FNLA Guest: Harold Bays, MD, FNLA Host: Alan S. Brown, MD, FNLA Guest: Matthew Ito, PharmD, FNLA Host Dr. Alan Brown is joined by an expert panel to discuss the NLA's latest draft document that will serve as recommendations to clinicians for the management of patients with dyslipidemia. The National Lipid Association's goal was to harmonize guidelines among what has been presented in the past by the ATP panel, the American College of Cardiology/American Heart Association Guidelines, and those also released in 2013 by the International Atherosclerosis Society. The NLA reaffirms the importance of understanding targets of treatment and goals for patients. Our expert panelists: Harold Bays, MD, FNLA - Medical Director and President of Louisville Metabolic and Atherosclerosis Research Center; co-author of the National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia and co-author of the American Society of Bariatric Physicians Obesity Algorithm Matthew Ito, PharmD, FNLA - Professor of Pharmacy Practice and Director of the Cardiovascular Pharmacodynamics Laboratory at Oregon State University/Oregon Health & Science University; member of the National Lipid Association Expert Panel on the Diagnosis and Treatment of Familial Hypercholesterolemia and the Recommendations for Patient-Centered Management of Dyslipidemia Carl E. Orringer, MD, FACC, FNLA - Associate Professor of Medicine, Cardiology Division at the University of Miami Medical Center; Editorial reviewer ...

Host: Alan S. Brown, MD, FNLA Is there a patient age at which statin therapy should be discontinued? Likewise, what does the current evidence tell us about initiating vs not initiating statin therapy in older patients? Joining Lipid Luminations to discuss these and other important questions is Dr. W. Virgil Brown, Charles Howard Candler Professor of Medicine Emeritus at Emory University School of Medicine in Atlanta, Georgia.

Host: Alan S. Brown, MD, FNLA Joining host Dr. Alan Brown is Dr. John Guyton, Associate Professor of Medicine and Assistant Professor of Pathology of the Division of Medicine-Endocrinology and Metabolism at Duke University School of Medicine. Their discussion will focus on data and results from HPS-2 THRIVE, a large-scale study comparing the use of statins and niacin versus statins alone. THRIVE stands for the Treatment of HDL to Reduce the Incidence of Vascular Events.

Host: Alan S. Brown, MD, FNLA Health information technologies have evolved dramatically from simplistic documentation devices early on to sophisticated drivers of quality patient care today. This emergence is having a particularly positive effect on treatment for dyslipidemia. Joining host Dr. Alan Brown to reflect on a recent NLA manuscript of HIT's impact toward adherence to lipid therapy is Dr. Jerome Cohen, Emeritus Professor of Internal Medicine at Saint Louis University School of Medicine and Director of Preventative Cardiology Program at the Saint Louis University Health Sciences Center. Dr. Cohen has been active in cardiovascular research for more than two decades.

Host: Alan S. Brown, MD, FNLA Host Dr. Alan Brown welcomes Dr. Marc Hamilton, Professor at Pennington Biomedical Research Center in Baton Rouge, LA. Their convesation focuses on the cardiometabolic consequences of lengthy sitting times, such as in people with "desk job careers."

Host: Alan S. Brown, MD, FNLA Joining host Dr. Alan Brown is Michael B. Bottorff, Pharm.D., Professor and Chair in the Department of Pharmacy Practice at South College School of Pharmacy in Knoxville, Tennessee. Dr. Bottorff will be reviewing generic medications, from manufacturing processes to approval measures.

Host: Alan S. Brown, MD, FNLA Speaking with host Dr. Alan Brown on the state of genetic testing for familial hypercholesterolemia (FH) is Dr. Joshua W. Knowles, MD, PhD, Instructor of Cardiovascular Medicine at Stanford University and Attending Physician of the Stanford Center for Inherited Cardiovascular Disease Familial Hypercholesterolemia (FH) Clinic.

Host: Alan S. Brown, MD, FNLA Dr. Alan Brown is joined by Dr. Bart Duell, director of the Lipid Disorders Clinic at the Oregon Health and Sciences University and one of the top winners in the NLA Abstracts program, to discuss research updates in Familial Hypercholesterolemia (FH).

Host: Alan S. Brown, MD, FNLA Postprandial hypertriglyceridemia occurs when the rapid absorption of dietary fat (in the form of chylomicron triglycerides) overwhelms the body's ability to clear plasma triglyceride. In its most severe form, postprandial hypertriglyceridemia can lead to chylomicronemia and a greatly increased risk of acute, life-threatening pancreatitis. Joining host Dr. Alan Brown to talk about this condition and a trial drug treatment in research and development is Dr. Dan Meyers, one of the top winners in the Abstracts Program of the National Lipid Association's Annual Scientific Sessions. Dr. Meyers is currently a Translational Medicine Expert with Novartis Institutes of Biomedical Research (NIBR) in Cambridge, MA. While at NIBR, he has designed and executed first-in-human, proof of concept, and mechanistic studies with novel compounds intended for the treatment of dyslipidemia, diabetes and related metabolic disease.

Host: Alan S. Brown, MD, FNLA Dr. Alan Brown is joined by Dr. Thomas Dayspring, Director of Cardiovascular Education for the Foundation for Health Improvement and Technology in Richmond, VA and clinical assistant professor of medicine at the UMDNJ - NJ Medical School. He is also a Fellow of both the American College of Physicians and the National Lipid Association. The two discuss Dr. Dayspring's research on discordances between LDL-P and ApoB, two biomarkers that are otherwise thought to correlate well with one another.

Host: Alan S. Brown, MD, FNLA Dr. Alan Brown welcomes Dr. Daniel J. Rader, Cooper-McLure Professor of Medicine and Pharmacology and Chief of the Division of Translational Medicine and Human Genetics at the Perelman School of Medicine at the University of Pennsylvania. Their discussion focuses on the clinical diagnosis, genetic complexity and prevalence of HoFH while exploring the current and novel modalities available to help HoFH patients achieve their LDL goals. Produced in Partnership with Supported by an Educational Grant from